REFERENCES
- Houshyar H, Galigniana M D, Pratt W B, Woods J H. Differential responsivity of the hypothalamic-pituitary-adrenal axis to glucocorticoid negative-feedback and corticotropin releasing hormone in rats undergoing morphine withdrawal: possible mechanisms involved in facilitated and attenuated stress responses. J Neuroendocrinol 2001; 13(10)875–886
- Houshyar H, Cooper Z D, Woods J H. Paradoxical effects of chronic morphine treatment on the temperature and pituitary-adrenal responses to acute restraint stress: A chronic stress paradigm. J Neuroendocrinol 2001; 13(10)862–874
- Gerra G, Ceresini S, Esposito A, Zaimovic A, Moi G, Bussandri M, Raggi M A, Molina E. Neuroendocrine and behavioural responses to opioid receptor-antagonist during heroin detoxification: Relationship with personality traits. Int Clin Psychopharmacol 2003; 18(5)261–269
- Schluger J H, Borg L, Ho A, Kreek M J. Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction. Neuropsychopharmacology 2001; 24(5)568–575
- Jiang Z N. Heroin Addiction and Contemporary Treatments, 1st Ed. Science Press, Beijing 1995
- Vale W, Vaughan J, Yamamoto G, Bruhn T, Douglas C, Dalton D, Rivier C, Rivier J. Assay of corticotropin releasing factor. Methods Enzymol 1983; 103: 565–577
- Ziolkowska A, Budzynska K, Trejter M, Tortorella C, Belloni A S, Malendowicz L K. Effects of adrenomedullin and its fragment 22–52 on basal and ACTH-stimulated secretion of cultured rat adrenocortical cells. Int J Mol Med 2003; 11(5)613–615
- Kennedy D M, Selby C, Lawson N. Measurement of urinary free cortisol using the Acs: 180 serum cortisol chemiluminescent immunoassay. Ann Clin Biochem 2000; 37: 520–528, (Pt4)
- Tang Y L, Zhao D, Zhao C, Cubells J F. Opiate addiction in China: Current situation and treatments. Addiction 2006; 101(5)657–665
- Milanes M V, Laorden M L, Chapleur-Chateau M, Burlet A. Differential regulation of corticotropin-releasing factor and vasopressin in discrete brain regions after morphine administration: Correlations with hypothalamic noradrenergic activity and pituitary-adrenal response. Naunyn Schmiedebergs Arch Pharmacol 1997; 356(5)603–610
- Kanchev L N, Baichev J, Kamenov I, Baikov B, Hallak A K. Melatonin, corticosterone, stress and phygocytic activity. Bulgarian J Veterinary Medicine 2006; 9(4)257–264
- Contoreggi C, Herming R I, Na P, Gold P W, Chrousos G, Negro P J, Better W, Cadet J L. Stress hormone responses to corticotropin-releasing hormone in substance abusers without severe comorbid psychiatric disease. Biol Psychiatry 2003; 54(9)873–878
- Nava F, Caldiroli E, Premi S, Lucchini A. Relationship between plasma cortisol levels, withdrawal symptoms and craving in abstinent and treated heroin addicts. J Addictive Diseases 2006; 25(2)9–16
- Pechnick R N. Effects of opioids on the hypothalamo-pituitary-adrenal axis. Annu Rev Pharmacol Toxicol 1993; 33: 353–382
- Maj M, Turchan J, Smialowska M, Przewlocka B. Morphine and cocaine influence on CRF biosynthesis in the rat central nucleus of amygdala. Neuropeptides 2003; 37(2)105–110
- Milanes M V, Laorden M L, Angel E, Tankosic P, Burlet A. Effect of naloxone-precipitated morphine withdrawal on CRH and vasopressin mRNA expression in the rat hypothalamic paraventricular nucleus. Neurosci Lett 2002; 334(1)58–62
- Hinz B, Hirschelmann R. Rapid non-genomic feedback effects of glucocorticoids on CRF-induced ACTH secretion in rats. Pharm Res 2000; 17(10)1273–1277
- Slominski A, Zbytek B, Zmijewski M, Slominski R M, Kauser S, Wortsman J, Tobin D J. Corticotropin releasing hormone and the skin. Front Biosci 2006; 11: 2230–2248